Today, there is a drug on the market specifically for Rhinosinusitis and Middle Effusive Otitis, characterized by precisely all three clinical manifestations: mucosal edema, slowing or stopping ciliary mobility and motility, and accumulation of mucous exudate. This product, which has been developed and patented by Italian researchers as well as tested with several clinical trials of national and international significance, is marketed under the brand name CiliaCell.